JM2 Capital Inc. Buys Shares of 2,519 AbbVie Inc.

The investment firm added to its position in the pharmaceutical giant during Q4 2025.

Apr. 14, 2026 at 12:36pm

Got story updates? Submit your updates here. ›

An extreme close-up of gleaming, heavy-duty banking equipment and machinery, conveying a sense of institutional financial power and security without using literal currency or charts.The acquisition of AbbVie shares by JM2 Capital reflects ongoing investor interest in the pharmaceutical industry's institutional machinery and financial infrastructure.North Chicago Today

JM2 Capital Inc. bought a new stake of 2,519 shares in AbbVie Inc. (NYSE:ABBV) during the fourth quarter of 2025, according to a recent SEC filing. The new position was valued at approximately $576,000.

Why it matters

AbbVie is one of the largest pharmaceutical companies in the world, with a diverse portfolio of blockbuster drugs. Institutional investors closely monitor changes in ownership of major healthcare stocks as they can signal broader market trends and investor sentiment.

The details

The filing shows JM2 Capital Inc. acquired the new position in AbbVie during the fourth quarter. Several other institutional investors and hedge funds also bought and sold ABBV shares during the same period, with some increasing and others decreasing their positions in the stock.

  • JM2 Capital Inc. bought the 2,519 shares of AbbVie in Q4 2025.

The players

JM2 Capital Inc.

An investment management firm that bought a new stake in AbbVie Inc. during the fourth quarter of 2025.

AbbVie Inc.

A global biopharmaceutical company that discovers, develops and commercializes therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The new position taken by JM2 Capital Inc. in AbbVie reflects ongoing investor interest in the pharmaceutical sector, particularly in large, diversified companies with established product portfolios and pipelines.